Collaboration builds on years of joint research, additional patent applications, and data from several clinical trials to accelerate therapeutic innovation in neurodegeneration LOS ANGELES / Jul 08, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has... Read More

LOS ANGELES / Jun 20, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London Conference, which will be held at the Four Seasons Hotel London at Park Lane in London, UK on June 24-26, 2025.... Read More

LOS ANGELES / Jun 11, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention , taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO... Read More

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases LOS ANGELES / Jun 09, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly... Read More

LOS ANGELES / Jun 04, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is... Read More

Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES / May 07, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent... Read More

Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion LOS ANGELES / May 05, 2025 / Business Wire / Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced... Read More

Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience’s commitment to advancing cutting-edge NAD+ and healthspan research LOS ANGELES / Apr 29, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the... Read More

LOS ANGELES / Apr 28, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will... Read More

The Company’s flagship patented nicotinamide riboside (NR) ingredient, Niagen ® , is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks LOS ANGELES / Apr 07, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on... Read More

Exclusively licensed from Queen’s University Belfast (QUB), this composition of matter patent, one of the most robust forms of intellectual property protection, grants Niagen Bioscience exclusive rights to various salt forms of NR and derivatives LOS ANGELES / Mar 20, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with... Read More

The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available LOS ANGELES / Mar 19, 2025 / Business Wire / Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,... Read More

LOS ANGELES / Mar 13, 2025 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a... Read More

LOS ANGELES / Mar 11, 2025 / Business Wire / ChromaDex Corp . (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference . ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels... Read More

Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. LOS ANGELES / Mar 04, 2025 / Business Wire / ChromaDex... Read More

LOS ANGELES / Feb 25, 2025 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be... Read More

LOS ANGELES / Dec 03, 2024 / Business Wire / ChromaDex Corp . (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc .’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large. This recognition underscores ChromaDex's industry-leading NAD+ research... Read More

The gold standard in NAD+ supplementation, Niagen ® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology’s new supplement LOS ANGELES / Nov 14, 2024 / Business Wire / ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR)... Read More

National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy LOS ANGELES / Nov 07, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV , now... Read More

Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 LOS ANGELES / Oct 31, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational... Read More

LOS ANGELES / Oct 24, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after... Read More

LOS ANGELES / Oct 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. The event is expected to feature 150 companies, presenting in half-hour increments, as well as... Read More

This award recognizes Dr. Nkrumah-Elie’s dedication to advancing scientific excellence for ChromaDex’s leading external research program and mentorship in the dietary supplement industry LOS ANGELES / Oct 15, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +... Read More

LOS ANGELES / Sep 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu,... Read More

LOS ANGELES / Sep 20, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations.... Read More

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to 14 new clinics LOS ANGELES / Sep 10, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research... Read More

Commemorating a quarter of a century with an exclusive 25% off lifelong subscription on Tru Niagen ® LOS ANGELES / Sep 09, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a century, ChromaDex has been at the forefront of analytical chemistry and scientific... Read More

LOS ANGELES / Aug 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, August 29, 2024, at 2:00 PM EDT. ChromaDex welcomes... Read More

Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months ended June 30, 2024. LOS ANGELES / Aug 07, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2024. Second Quarter 2024 Financial and Recent... Read More

LOS ANGELES / Aug 05, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Interim Chief Financial Officer, James Lee, will participate at Canaccord Genuity’s 44th Annual Growth Conference, taking place from August 13 to 15, 2024, at the InterContinental in... Read More

LOS ANGELES / Jul 24, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2024. The financial results will be reported in a press release after the... Read More

Results from the at-home test kit are available to HCPs and their patients through 1health LOS ANGELES / Jul 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit *, now available... Read More

LOS ANGELES / Jul 22, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today,... Read More

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV LOS ANGELES / Jul 16, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on... Read More

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio LOS ANGELES / Jul 01, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, today announced its inclusion in the Russell 2000 ® Index as... Read More

NR improved the six-minute walking distance and treadmill walking time for those with PAD LOS ANGELES / Jun 24, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside (NR) supplementation for people with peripheral artery disease (PAD).... Read More

Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized nicotinamide riboside chloride (NRC) for compounding by 503B outsourcing facilities, which will soon be available to ship to clinics nationwide. LOS ANGELES /... Read More

ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT LOS ANGELES / Jun 07, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and... Read More

LOS ANGELES / Jun 04, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST. ChromaDex welcomes stakeholders, investors,... Read More

LOS ANGELES / May 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs.... Read More

Judges award Niagen for its “high-quality, unparalleled” healthy aging research LOS ANGELES / May 22, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce that its flagship ingredient, Niagen ® (patented... Read More

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. LOS ANGELES / May 08, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent... Read More

New ingredient collaboration debuts Solgar’s first NAD + boosting supplement and reinforces NIAGEN as the gold standard in the NAD + supplement category LOS ANGELES / Apr 30, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces an ingredient partnership with Solgar ® , a Nestlé Health Science brand. Solgar’s inaugural... Read More

Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements™ and online at www.vitaminshoppe.com LOS ANGELES / Apr 25, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces that its... Read More

LOS ANGELES / Apr 24, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular... Read More

Tru Niagen ® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states LOS ANGELES / Apr 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † , is now available at Sprouts... Read More

All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport ® ) are Alkemist Assured LOS ANGELES / Mar 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces that its flagship Tru Niagen ®... Read More

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. LOS ANGELES / Mar 06, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023... Read More

LOS ANGELES / Feb 21, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market... Read More

LOS ANGELES / Feb 05, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders,... Read More

LOS ANGELES / Jan 26, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings... Read More

Tru Niagen is now available to US troops through an exclusive Military program LOS ANGELES / Dec 20, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. As the most efficient, studied, and high-quality NAD+ boosting supplement on the market, ChromaDex’s... Read More

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. SAN DIEGO , Dec. 12, 2023 /PRNewswire/ -- Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since... Read More

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day LOS ANGELES / Nov 30, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares results from a... Read More

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated LOS ANGELES / Nov 15, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD + ) and healthy aging research, shares... Read More

LOS ANGELES / Nov 09, 2023 / Business Wire / ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders,... Read More

Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. LOS ANGELES / Nov 08, 2023 / Business Wire / ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sales... Read More

Tru Niagen ® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD + levels by up to 150% in as little as three weeks LOS ANGELES / Nov 01, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and... Read More

LOS ANGELES / Oct 31, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023. The financial results will be reported in a press release after the close of regular stock market... Read More

The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws ® , debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Niagen ® LOS ANGELES / Oct 26, 2023 / Business Wire /... Read More

Celebrating a significant achievement in NAD + research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders LOS ANGELES / Oct 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy aging,... Read More

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES / Aug 24, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy... Read More

Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. LOS ANGELES / Aug 09, 2023 / Business Wire / ChromaDex Corp . (NASDAQ:CDXC) today announced financial results for the second quarter of 2023. Second Quarter 2023 and Recent Highlights... Read More

This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. LOS ANGELES / Aug 08, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.... Read More

Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16 LOS ANGELES / Aug 07, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation... Read More

LOS ANGELES / Aug 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the... Read More

Abstracts recently published in the Association for Research in Vision and Ophthalmology (ARVO) journal showcase NR, one of the most efficient and well-researched NAD+ precursors, prevented the worsening of visual field sensitivity in glaucoma patients, and builds on research demonstrating decreased cellular NAD+ levels and impaired mitochondrial function are associated with Primary open-angle glaucoma (POAG) LOS ANGELES /... Read More

Through CERP™, over 275 global research agreements with 235+ independent, expert investigators are uncovering the full potential of NAD+ by researching ChromaDex’s Niagen® ingredient, patented nicotinamide riboside (NR), one of the most studied and efficient modern NAD+ precursors in the healthy aging space, among other ingredients LOS ANGELES / Jun 16, 2023 / Business Wire / On June 13th, ChromaDex Corp . (NASDAQ:CDXC), a... Read More

LOS ANGELES / May 30, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings. ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer,... Read More

LOS ANGELES / May 11, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday,... Read More

Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023. LOS ANGELES / May 10, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023. First Quarter 2023 and Recent Highlights Total net... Read More

LOS ANGELES / May 02, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading... Read More

LOS ANGELES / Mar 08, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 and Recent Highlights Total net sales were $21.0 million, up 18% from $17.8 million for the prior year quarter. Tru Niagen® net sales were $16.1 million, up 14% from $14.1 million for the prior year quarter. Selling and marketing expense as a percentage of net... Read More

LOS ANGELES / Mar 06, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The Annual ROTH Conference is one of the largest in the nation for small-cap companies and combines company presentations, Q&A... Read More

LOS ANGELES / Feb 27, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year, which ended December 31, 2022. The financial results will be reported in a press release after the close of regular... Read More

LOS ANGELES / Feb 22, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and related derivatives, some of the most efficient nicotinamide adenine dinucleotide (NAD+) precursors, and today announced it expanded this patent family with newly granted U.S. Patent... Read More

This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers LOS ANGELES / Jan 31, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational... Read More

NR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led... Read More

Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative... Read More

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex since August 11, 2022, and prior to that was the Vice President of Finance and Investor Relations of ChromaDex since September 17,... Read More

Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen ® ingredient (patented nicotinamide riboside or... Read More